NEOGENOMICS INC — Director's Dealing 2020

Mar 4, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NEOGENOMICS INC (NEO)
CIK: 0001077183
Period of Report: 2020-03-01

Reporting Person: McKenzie Kathryn B (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-03-01	Common Stock	F	168	—	Disposed	2105	Direct
2020-03-02	Common Stock	A	5824	—	Acquired	7929	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-03-02	Common Stock	$28.33	A	37514	Acquired	2027-03-02	Common Stock (37514.0)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$9.07	2022-10-18	Common Stock (25000.0)	25000	Direct
Stock Option (Right to Buy)	$8.03	2023-02-26	Common Stock (40000.0)	40000	Direct
Stock Option (Right to Buy)	$19.6	2024-03-01	Common Stock (13894.0)	13894	Direct

Footnotes

F1: Shares withheld by NeoGenomics Inc. to satisfy the tax obligations in connection with the March 1, 2020 vesting of restricted stock.

F2: On October 17, 2017, Ms. McKenzie was granted 25,000 stock options. These options vest ratably over the first three anniversary dates of the grant date.

F3: On February 26, 2018, Ms. McKenzie was granted 48,000 stock options. These options vest ratably over the first three anniversary dates of the grant date.

F4: On March 1, 2019, Ms. McKenzie was granted 13,894 stock options. These options vest ratably over the first four anniversary dates of the grant date.

F5: On March 2, 2020, Ms. McKenzie was granted 37,514 stock options. These options vest ratably over the first four anniversary dates of the grant date.